Envestnet Asset Management
GBT

Envestnet Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Envestnet Asset Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,125
Closed -$285K – 3794
2021
Q2 		$285K Sell
8,125
-1,405
-15% -$54.9K ﹤0.01% 3318
2021
Q1 		$388K Sell
9,530
-1,334
-12% -$61.3K ﹤0.01% 2995
2020
Q4 		$471K Buy
+10,864
New +$536K ﹤0.01% 2687

Other funds holding GBT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Envestnet Asset Management's GBT Position: Q3 2021 in Review

Envestnet Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2021, closing a stake of 8,125 shares — an estimated $285K sold.

Envestnet Asset Management first reported a position in GBT in Q4 2020 and held it in 3 quarters. The position peaked at $471K in Q4 2020. 187 funds tracked by Wall St. Rank hold GBT as of Q3 2021.

  • Envestnet Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Envestnet Asset Management sold 8,125 Global Blood Therapeutics, Inc. shares in Q3 2021, an estimated $285K.
  • Envestnet Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 3 quarters.
  • Envestnet Asset Management's Global Blood Therapeutics, Inc. position peaked at $471K in Q4 2020.
  • 187 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2021.

Based on Envestnet Asset Management's 13F filing for Q3 2021, filed 7 Oct 2021.